May 2016: CureMeta CEO Michael Schopperle talks at America's Antibody Congress

Boston-based biotechnology company CureMeta LLC, a company advancing novel antibody drug conjugates (ADCs) targeting pluripotent stem cells, is due to present at America’s Antibody Congress 2016 on the 19th-20th of May in San Diego, CA. CureMeta CEO Michael Schopperle will be giving a talk regarding the company’s research pipeline. 

 

March 2016: Dr. Glenn J. Bubley of Beth Israel Deaconess Medical Center presents at the Ninth Annual Prostate Cancer Program Retreat

CureMeta LLC research was presented during the Ninth Annual Prostate Cancer Program Retreat in Fort Lauderdale, FL on the 13th-15th of March 2016.  Beth Israel Deaconess Medical Center Oncologist Glenn J. Bubley presented research entitled “Identification of Circulating Pluripotent Cancer Stem Cells in the Blood of Prostate Cancer Patients for the Diagnosis of Metastatic Cancer”.

 

March 2016: University of Texas SouthWestern researcher presents at Molecular Med Tri-Conference Meeting

CureMeta LLC presented research during the Molecular Med Tri-Con 2016 Conference in San Francisco, CA on the 6th-11th of March. University of Texas Southwestern researcher Claudia Schaefer presented“Identification of Circulating Pluripotent Cancer Stem Cells in the Blood of Prostate Cancer Patients for the Diagnosis of Metastatic Cancer”.

 

January 2016: CureMeta presents talk at CHI Peptalk Conference San Francisco

CureMeta LLC presented at the Cambridge Health Institute’s Peptalk 2016 on the 18th-22nd of January in San Francisco, CA. CureMeta CEO Michael Schopperle held a talk regarding CureMeta’s pipeline research discussing the company’s studies using novel ADCs developed by CureMeta as new therapeutics for metastatic and aggressive cancers. 

 

January 2016: CureMeta LLC CEO presents at EBD’s Biotech Showcase

CureMeta LLC presented at the Biotech Showcase 2016 in San Francisco, CA on the 11th-13th January 2016. CureMeta CEO Michael Schopperle gave a talk explaining the company mission to develop novel therapeutics for the treatment of aggressive and metastatic solid tumors. 

 

December 2015: Research Collaboration begins with Weinberg Lab/MIT

Starting in December of 2015 CureMeta LLC began a research collaboration with Professor Robert Weinberg of the Whitehead Institute of MIT. The Weinberg lab will use cancer specific antibodies developed by CureMeta in their human breast cancer mouse models to identify and characterize breast cancer stem cells. 

 

September 2015: CureMeta CEO Michael Schopperle speaks at PEGS Korea 2015

CureMeta LLC presented at the essential Protein Engineering Summit on the 1st-3rd of September 2015. CEO Michael Schopperle presented a talk entitled “Antibody-Drug Conjugates Targeting Embryonic and Pluripotent Stem Cell Markers as Novel Therapeutics for Metastatic Cancers”.  

 

October 2015:  Ash Stevens begins research collaboration with CureMeta LLC

CureMeta LLC has begun a research collaboration with Ash Stevens in Riverview, Michigan.  Ash Stevens, with 50 years of expertise manufacturing active pharmaceutical ingredients for cancer drugs, will be working with CureMeta on developing new toxic payloads for generation of novel Antibody-Drug-Conjugate therapeutics.

 

August 2015: CureMeta CEO Michael Schopperle invited to speak at Taipei-based IADDS conference 

CureMeta LLC presented at the International Advanced Drug Delivery Symposium on the 31st of August-1st of September in Taipei, Taiwan. CEO Michael Schopperle was invited to speak and held a talk presenting CureMeta’s novel approach to cancer and R&D pipeline.

 

May 2015: CureMeta presents at IBC Life Sciences 

CureMeta LLC presented at the IBC Life Science Conference in San Francisco, CA on the 18th-20th of May 2015. CureMeta’s senior scientist Edwin Tan presented “ADCs Targeting Pluripotent Stem Cells” at the poster sessions.

 

June 2015: CureMeta begins research collaboration with Viola-Villegas Lab / Karmanos Cancer Institute

As of June 2015, CureMeta began a research collaboration with the Viola-Villegas Lab at the Karmanos Cancer Institute. Research will focus on using CureMeta’s embryonic-specific antibodies as tools for cancer imaging/detection studies in human cancer mouse models. 

 

May 2015: Seaport-based biotech CureMeta LLC gives 2 talks and 4 presentations at PEGS Boston 2015

CureMeta LLC, a biotechnology company focused on antibody drug conjugate therapies for metastatic cancers, presented at the essential Protein Engineering Summit on the 4th-8th of May 2015. CEO Michael Schopperle and scientist Yawen Ju both held oral presentations. 

 

February 2015: CureMeta presents at Keystone Symposia in Banff, Canada

CureMeta LLC presented at the Keystone Symposia in Banff, Canada on the 8th-13th of February 2015. VP of Operations Mats Holmqvist presented a poster entitled “ADCs Targeting Pluripotent Stem Cells”.

 

January 2015:  Dana Farber/ Harvard Cancer Center initiates research collaboration with CureMeta LLC

Starting in January of 2015 CureMeta LLC initiated a research collaboration with Glenn J. Bubley, a director of Medical Oncology at the Beth Israel Deaconess Medical Center based in Boston, MA. The study will focus on using cancer stem cell specific antibodies developed at CureMeta to characterize circulating tumor cells in blood of patients with prostate cancer.  This research collaboration will further validate CureMeta’s approach to understanding metastatic cancer.

 

December 2014: CureMeta announces research collaboration with UT Southwestern

Starting in December of 2014 CureMeta LLC began a research collaboration with the University of Texas Southwestern, well-known for their comprehensive, nationally recognized cancer research facilities. Dr. Claudia Schaefer in the Danuser lab will use CureMeta developed antibodies to analyze and characterize circulating tumor cells.

 

October 2014: Karmanos and CureMeta presents at Prostate Cancer Foundation meeting

CureMeta LLC presented at research sessions during the 22nd Annual Prostate Cancer Foundation (PCF) Scientific Retreat in Carlsbad, CA on the 23rd-25th of October. CureMeta’s collaborator Elizabeth Heath, Professor of Oncology and Medicine, and Director of Prostate Cancer Research at Karmanos Cancer Institution presented “A Study of Human Pluripotent Stem Cell Markers in Prostate Cancer Tissue”  

 

September 2013: Karmanos Cancer Institute and CureMeta LLC start research collaboration

CureMeta LLC initiated a research collaboration with the Barbara Ann Karmanos Cancer Institute in Detroit, MI to study the presence of embryonic cancer stem cell markers in prostate cancer.  The goal of the collaboration is to develop novel diagnostic prostate cancer tests. 

 

March 2012: CureMeta Starts R&D in new Seaport Lab

As of March 2012, CureMeta’s new lab build-out was completed and research development began with the goal of generating novel cancer therapeutics for the treatment and cure of aggressive and metastatic human cancers.